Desmopressin
Also known as: DDAVP, 1-deamino-8-D-arginine vasopressin, dDAVP, Minirin, Stimate, Noctiva, Nocdurna, desmopressin acetate
Synthetic vasopressin analog; antidiuretic hormone (ADH) agonist; hemostatic agent
What it is
Desmopressin (DDAVP) is a synthetic hormone used to treat conditions where the body struggles to retain water or stop bleeding. It helps kidneys conserve water, reducing excessive urination in diabetes insipidus and bedwetting, and temporarily boosts clotting factors in mild hemophilia and von Willebrand disease. FDA-approved since the 1970s, it is available by prescription in intranasal, oral, and injectable forms.
The scientific side
Desmopressin is a synthetic structural analog of arginine vasopressin (AVP), the endogenous antidiuretic hormone. It was engineered by deaminating the amino-terminal cysteine and substituting D-arginine at position 8, which dramatically increases antidiuretic potency, extends half-life, and eliminates the vasopressor activity of native vasopressin. Desmopressin exerts its primary antidiuretic effect by selectively binding to vasopressin V2 receptors on principal cells of the renal collecting duct. V2 receptor activation stimulates adenylyl cyclase via Gs coupling, raising intracellular cAMP, which causes phosphorylation and membrane insertion of aquaporin-2 (AQP2) water channels. This dramatically increases collecting duct water permeability, enabling passive water reabsorption down the osmotic gradient established by the renal medulla and thereby concentrating urine and reducing urine output. In central (neurogenic) diabetes insipidus — where the posterior pituitary fails to produce sufficient AVP — exogenous desmopressin fully substitutes for the deficient hormone and corrects polyuria and polydipsia. In primary nocturnal enuresis and nocturia, the same V2-mediated antidiuretic mechanism reduces nocturnal urine production, preventing bladder overfilling during sleep. Desmopressin also activates V2 receptors on vascular endothelium, which triggers the exocytosis of Weibel-Palade bodies from endothelial cells. This releases von Willebrand factor (VWF) multimers and simultaneously liberates coagulation factor VIII from its VWF carrier, raising circulating VWF and Factor VIII levels by two- to five-fold within 30 to 90 minutes. This hemostatic mechanism is the basis for its use in mild hemophilia A and von Willebrand disease type 1, as well as to reduce perioperative bleeding. In Cushing disease, desmopressin paradoxically stimulates ACTH release from corticotropinoma cells via anomalous AVPR1b receptor expression, forming the basis of the desmopressin stimulation test used in the differential diagnosis of ACTH-dependent Cushing syndrome. The antidiuretic potency of desmopressin without vasopressor activity and its predictable half-life of 2–4 hours makes it one of the most widely used synthetic hormone replacements in clinical endocrinology and hematology.
Class: Synthetic vasopressin analog; antidiuretic hormone (ADH) agonist; hemostatic agent
Administration & storage
- Administration
- Intravenous infusion: dilute injectable solution in 50 mL normal saline and infuse over 15–30 minutes for hemostatic indicationsSubcutaneous injection: same dose as IV for hemostatic indications in outpatient settingsIntranasal (metered spray or rhinal catheter): widely used for DIenuresisand hemostatic indicationsSublingual/oral: for nocturia and enuresis; must be taken on an empty stomach or after light meal for consistent absorption
- Storage
- Injectable and intranasal solutions: refrigerate at 2–8°C (36–46°F); do not freeze. Oral tablets and sublingual lyophilisate: store at room temperature 15–25°C (59–77°F), protected from moisture. Once opened, intranasal spray bottles are stable at room temperature for up to 3–4 weeks depending on formulation.
- Cautions
- HYPONATREMIA RISK: Most important safety concern. Desmopressin causes water retention — if fluid intake is not restricted, dangerous dilutional hyponatremia can occur, leading to seizures and death. Fluid restriction is MANDATORY with all desmopressin formulations (PMID 15947670, 8700794, 32119469).,CONTRAINDICATED in patients with primary polydipsia (psychogenic or habitual excessive fluid intake) — cannot restrict intake, making severe hyponatremia inevitable.,Drug interaction: NSAIDs (including meloxicam) potentiate desmopressin's antidiuretic effect, markedly increasing hyponatremia risk. Case report of hyponatremia with seizure from meloxicam-desmopressin interaction (PMID 31084937).,Intranasal absorption is highly variable (affected by nasal congestion, rhinitis); switch to oral or SC formulation if nasal administration is unreliable.,Tachyphylaxis develops with repeated hemostatic doses — efficacy diminishes with dosing more frequently than every 48–72 hours; plasma factor levels should be monitored.,Use with caution in the elderly, patients with heart failure, renal impairment, or any condition predisposing to fluid retention — increased hyponatremia risk.,Monitor serum sodium before initiating therapy, at day 3–7, and after any dose increase. Particular vigilance required in children, elderly, and postoperative patients.
Legal & regulatory status
FDA-approved. Multiple approved indications: (1) central diabetes insipidus — intranasal, oral, and injectable formulations; (2) primary nocturnal enuresis in children ≥6 years — oral tablets and intranasal spray; (3)…
Desmopressin is not included on the current WADA Prohibited List as a performance-enhancing substance. Its primary pharmacological actions (antidiuresis, clotting factor release) do not confer athletic performance…
Health Canada has approved desmopressin (as DDAVP and generic equivalents) for central diabetes insipidus, primary nocturnal enuresis, and mild hemophilia A / von Willebrand disease. Formulations include intranasal…
What it's studied for
- Primary nocturnal enuresis (bedwetting) in children Phase III RCT
- Nocturia in adult men Phase III RCT
- Central (neurogenic) diabetes insipidus Human RCT
- Mild hemophilia A and von Willebrand disease — perioperative and bleeding management Human RCT
- Perioperative bleeding reduction during cardiac surgery Human RCT
- Desmopressin stimulation test for Cushing disease diagnosis Human observational
- Hyponatremia correction — controlled desmopressin clamping strategy Human observational
Safety signals
- Symptomatic hyponatremia and water intoxication
- Drug interaction: NSAIDs potentiate antidiuretic effect, increasing hyponatremia risk
- Tachyphylaxis with repeated hemostatic dosing
- Hyponatremia risk with rapid correction causing osmotic demyelination syndrome
- Variable pharmacokinetic response requiring individual dose titration
- Headache, nausea, and flushing with IV administration
Contraindications
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Unspecified | 0.1–0.4 mg orally (oral tablet) OR 10–40 µg intranasally (metered nasal spray) | — | Children with primary nocturnal enuresis | Research |
| Unspecified | 25 µg orally (women) or 50 µg orally (men) — sublingual lyophilisate formulation (Nocdurna) | — | Adults with nocturia due to nocturnal polyuria | Research |
| Unspecified | 0.1–0.8 mg orally per day (divided doses) OR 10–40 µg intranasally per day (1–3 doses) OR 1–4 µg SC/IV | — | Adults with central diabetes insipidus | Research |
| Unspecified | 0.3 µg/kg IV or SC (max 20–24 µg per dose) OR 150–300 µg intranasally (Stimate) | — | Adults/children with mild hemophilia A or VWD type 1 — perioperative | Research |
| oral, sublingual, intranasal, subcutaneous, or intravenous depending on indication | 0.1–0.4 mg orally for enuresis/nocturia; 0.3 µg/kg IV/SC for hemostatic indications; 10–40 µg intranasally for DI or enuresis | once nightly (enuresis, nocturia); 2–3 times daily (central DI); single pre-procedural dose (hemostatic use) | children and adults using desmopressin for its FDA-approved indications (nocturnal enuresis, nocturia, central diabetes insipidus, or bleeding disorders) |